REG - Futura Medical PLC - Notice of AGM and Availability of Annual Report

Futura MedicalAnnouncement

01/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA4478Na&default-theme=true

RNS Number : 4478N  Futura Medical PLC  01 June 2022

 

 

1 June 2022

 

 Futura Medical plc

("Futura" or the "Company")

Notice of AGM and Availability of Annual Report

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, today
announces its Annual General Meeting ("AGM") will be held at 10:00 am on
Tuesday 28 June 2022 at the offices of Liberum Capital Limited, Ropemaker
Place, 25 Ropemaker Street, London EC2Y 9LY.

 

Following the easing of coronavirus (COVID-19) restrictions in the UK, the
Board has made arrangements to enable shareholders to attend the Annual
General Meeting in person. However, in light of the uncertainty as to any
further COVID-19 measures that may be put in place by the UK Government and
bearing in mind the inherent risk of large gatherings, the Company encourages
shareholders to consider submitting their voting instructions in advance by
appointing the Chairman of the meeting as their proxy, rather than attending
and voting on the day. This will ensure that votes are registered in
accordance with shareholders' wishes regardless of any restrictions or
disruption around the Annual General Meeting and will also help protect the
health and safety of shareholders, directors and other necessary attendees.
Depending on the public health situation, we may impose additional procedures
or limitations on attendees beyond any described in this Notice of Annual
General Meeting.

 

If you wish to attend the meeting in person, please register your interest,
prior to 10:00 a.m. on 24 June 2022 at investor.relations@futuramedical.com.

 

The Company requests that anyone who has recently tested positive for COVID-19
and/or is showing symptoms, or anyone who lives with somebody who has recently
tested positive, does not attend the meeting

 

Shareholders are asked to cast their vote as follows: (1) casting your proxy
vote online by logging on to www.signalshares.com
(https://www.signalshares.com/) and following the instructions; or (2) in the
case of CREST members, by utilising the CREST electronic proxy appointment
service; or (3) requesting a hard copy form of proxy directly from the
registrars, Link Group. If you choose to attend the Annual General Meeting in
person instead of appointing the Chairman of the meeting as proxy as we
strongly recommend, you will still be able to vote in person at the Annual
General Meeting.

 

If you are not attending the Annual General Meeting in person, your proxy vote
will need to be lodged by 10:00 a.m. on 24 June 2022 as no online voting will
take place in-real time during the meeting itself.

 

The Company will operate an audio dial-in facility to allow shareholders to
listen to the business of the meeting: shareholders will need to be confirmed
as a shareholder or present a letter of representation before details of how
to access this facility are released to them via email the morning of the
meeting. You can request access by emailing:
investor.relations@futuramedical.com prior to 10:00 a.m. on 24 June 2022.

 

This document should be read in conjunction with the Futura Medical plc annual
report and accounts. If you are in any doubt as to the action you should take,
you are recommended to seek your own personal financial advice immediately
from your stockbroker, bank manager, solicitor, accountant or independent
advisor, who, if you are taking advice in the United Kingdom, is authorised
pursuant to the Financial Services and Markets Act 2000.

 

Shareholders will not get an opportunity to vote or ask questions or any other
participation during the call.

 

The situation in relation to COVID-19 is constantly evolving, and the UK
Government may change current restrictions or implement further measures
relating to the holding of Annual General Meetings during the affected period.
We will continue to monitor the situation, and any changes to the Annual
General Meeting will be communicated to shareholders before the meeting
through our website and, where appropriate, by stock exchange announcement.

 

Annual Report

Futura's annual report and accounts for the year ended 31 December 2021 (the
"Annual Report") is available to shareholders as an electronic communication
pursuant to the Companies Act 2006 and is now available at the Company's
website www.futuramedical.com
(http://www.futuramedical.com/investor-centre/corporate-documentation.) ,
along with the Notice of AGM.

 

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is CE
marked in Europe and the UK as a clinically proven topical treatment
for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(https://www.futuramedical.com/)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAZFLFXLELZBBB